Literature DB >> 29991932

Improving IBD Care: A Personalized Approach to Management.

Stephen B Hanauer1.   

Abstract

Year:  2018        PMID： 29991932      PMCID： PMC6018320     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  108 in total

1.  Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial.

Authors:  Richard J Farrell; Mazen Alsahli; Yoon-Tae Jeen; Kenneth R Falchuk; Mark A Peppercorn; Pierre Michetti
Journal:  Gastroenterology       Date:  2003-04       Impact factor: 22.682

2.  Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects.

Authors:  Matthieu Allez; Konstantinos Karmiris; Edouard Louis; Gert Van Assche; Shomron Ben-Horin; Amir Klein; Janneke Van der Woude; Filip Baert; Rami Eliakim; Konstantinos Katsanos; Jørn Brynskov; Flavio Steinwurz; Silvio Danese; Severine Vermeire; Jean-Luc Teillaud; Marc Lémann; Yehuda Chowers
Journal:  J Crohns Colitis       Date:  2010-06-29       Impact factor: 9.071

3.  Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee.

Authors:  Asher Kornbluth; David B Sachar
Journal:  Am J Gastroenterol       Date:  2010-01-12       Impact factor: 10.864

Review 4.  American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease.

Authors:  Joseph D Feuerstein; Geoffrey C Nguyen; Sonia S Kupfer; Yngve Falck-Ytter; Siddharth Singh
Journal:  Gastroenterology       Date:  2017-08-03       Impact factor: 22.682

5.  Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.

Authors:  Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts
Journal:  Lancet       Date:  2002-05-04       Impact factor: 79.321

6.  Vaccinating Patients With Inflammatory Bowel Disease.

Authors:  Jason Reich; Sharmeel Wasan; Francis A Farraye
Journal:  Gastroenterol Hepatol (N Y)       Date:  2016-09

Review 7.  The clinical potential of etrolizumab in ulcerative colitis: hypes and hopes.

Authors:  Gionata Fiorino; Daniela Gilardi; Silvio Danese
Journal:  Therap Adv Gastroenterol       Date:  2016-05-19       Impact factor: 4.409

8.  Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis.

Authors:  Remo Panaccione; Subrata Ghosh; Stephen Middleton; Juan R Márquez; Boyd B Scott; Laurence Flint; Hubert J F van Hoogstraten; Annie C Chen; Hanzhe Zheng; Silvio Danese; Paul Rutgeerts
Journal:  Gastroenterology       Date:  2014-02       Impact factor: 22.682

9.  Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study.

Authors:  Simon P L Travis; Silvio Danese; Limas Kupcinskas; Olga Alexeeva; Geert D'Haens; Peter R Gibson; Luigi Moro; Richard Jones; E David Ballard; Johan Masure; Matteo Rossini; William J Sandborn
Journal:  Gut       Date:  2013-02-22       Impact factor: 23.059

10.  Ferumoxytol versus placebo in iron deficiency anemia: efficacy, safety, and quality of life in patients with gastrointestinal disorders.

Authors:  David C Ford; Naomi V Dahl; William E Strauss; Charles F Barish; David J Hetzel; Kristine Bernard; Zhu Li; Lee F Allen
Journal:  Clin Exp Gastroenterol       Date:  2016-07-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.